pirfenidone has been researched along with Diffuse Cutaneous Systemic Sclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| McMahan, ZH; Volkmann, ER | 1 |
| Azuma, A; Fujita, K; Hayashihara, K; Miura, Y; Nei, T; Rin, S; Saito, T; Sekine, A; Takoi, H; Tanaka, T; Tsunoda, Y; Yatagai, Y | 1 |
1 review(s) available for pirfenidone and Diffuse Cutaneous Systemic Sclerosis
| Article | Year |
|---|---|
An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis.
Topics: Autoantibodies; Clinical Trials as Topic; Cyclophosphamide; Drugs, Investigational; Humans; Lung Diseases, Interstitial; Mycophenolic Acid; Pyridones; Rituximab; Scleroderma, Diffuse; Scleroderma, Systemic; Treatment Outcome | 2020 |
1 other study(ies) available for pirfenidone and Diffuse Cutaneous Systemic Sclerosis
| Article | Year |
|---|---|
Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease.
Topics: Aged; Female; Humans; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Pyridones; Recovery of Function; Retrospective Studies; Scleroderma, Diffuse; Scleroderma, Localized; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vital Capacity | 2014 |